Evidence map›Paper›PMID 40295988›Full record

ArticleBMC infectious diseases2025

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.

Dalia Salem, Ahmed El-Shenawy, Heba Dahroug, Manar Zaiton, Doaa Gamal, Manal Diab

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dalia SalemMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt. drdaliasalem@gmail.com.
Ahmed El-ShenawyMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt.
Heba DahrougMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt.
Manar ZaitonMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt.
Doaa GamalMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt.
Manal DiabMicrobiology Department, Theodor Bilharz Research Institute (TBRI), Postal Address: 30 Imbaba, P.O Box 12411, Giza, Egypt.

Funding

Theodor Bilharz Research Institute 113 D
6 · The paper itself

Abstract

backgroundCarbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities. Ceftazidim/avibactam and ceftolozane/tazobactam have a potential role in treatment of multi-drug resistant phenotypes including carbapenem resistant P. aeruginosa. Therefore, we aimed to assess the in vitro antimicrobial activity of ceftazidime/avibactam and ceftolozane/tazobactam against carbapenem-resistant P. aeruginosa (CRPA) strains with different β-lactamase/carbapenemase genes.

methodsSixty CRPA isolates identified from clinical samples were examined for antimicrobial susceptibility including ceftazidim/avibactam and ceftolozane/tazobactam by Vitek2 compact system, and carbapenemase production by modified carbapenem inactivation method (mCIM) test and carbapenemase producing genes by polymerase chain reaction (PCR).

resultsIsolates were resistant to imipenem in 96.7% and meropenem in 88.3%. of isolates. Carbapenemase production by mCIM test was 70% compared to 73.3% by (PCR). Carbapenemase encoding genes bla

conclusionModified carbapenem inactivation method test gave satisfactory results and could be used as an alternative to expensive genotypic methods. Ceftazidim/avibactam and ceftolozane/tazobactam were unsuccessful against carbapenem resistant P. aeruginosa isolates carrying carbapenemase genes especially metallo-β lactamase genes. Therefore, it is essential to detect susceptibility patterns to newly introduced β-Lactam/β-Lactamase inhibitor combinations due to the emerging resistance to these therapeutics.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeCephalosporinsPseudomonas aeruginosaTazobactamBacterial Proteinsbeta-LactamasesCarbapenemsDrug CombinationsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsTazobactamCarbapenem resistant P. aeruginosaCeftazidim/avibactamCeftolozane/tazobactamModified carbapenem inactivation method testβ-Lactam/β-Lactamase inhibitor combinations

Identifiers

PMID40295988
PMCPMC12039273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.